ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΠΊΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΠ½Π°ΡΡΡΠΎΠ·ΠΎΠ»Π°
ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½Ρ Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² Π°Π½Π°ΡΡΡΠΎΠ·ΠΎΠ»Π° ΠΏΠΎΡΠ»Π΅ ΠΎΠ΄Π½ΠΎΠΊΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΠ΅ΠΌΠ° Π½ΠΎΠ²ΡΡ Π΄ΠΆΠ΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠ°Π±Π»Π΅ΡΠΎΠΊ ΠΠ½Π΅ΡΡΠ΅ΡΠ° ΠΈ ΠΠ΅ΡΠΎ-Π°Π½Π°ΡΡΡΠΎΠ·ΠΎΠ». ΠΠ»Ρ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π²ΠΎΠΏΡΠΎΡΠ° ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΠΈ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΠ½Π΅ΡΡΠ΅ΡΠ° ΠΈ ΠΠ΅ΡΠΎ-Π°Π½Π°ΡΡΡΠΎΠ·ΠΎΠ» ΠΏΠΎΠΊΠ°Π·Π°Π½Π° ΠΈΡ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ ΠΡΠΈΠΌΠΈΠ΄Π΅ΠΊΡ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΠΏΡΠ΅Π΄ΡΡΠΎΡΡΠΈΠΌ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠ°Π±Π»Π΅ΡΠΎΠΊ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²-Π΄ΠΆΠ΅Π½Π΅ΡΠΈΠΊΠΎΠ²… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ³Π°ΡΠΎΠ½ΠΎΠ² Π.Π., ΠΠΈΠΎΡΡΠΎΠ²ΡΠΊΠΈΠΉ Π. Π. ΠΡΠΎΠ³ΡΠ°ΠΌΠΌΠ° M-IND-ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ ΠΌΠΎΠ΄Π΅Π»ΡΠ½ΠΎ-Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΌΠΎΠΌΠ΅Π½ΡΠΎΠ² // Π₯ΠΈΠΌΠΈΠΊΠΎ-ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π». 1991. № 10. Π‘. 16−19.
- ΠΠ΅ΡΠ΅Π·ΠΎΠ²ΡΠΊΠ°Ρ Π.Π., ΠΠ²Π°Π½ΠΎΠ²Π° Π. Π. ΠΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² // ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² Π² Π ΠΎΡΡΠΈΠΈ.-2004.-№ 3−4. Π‘. 16−23.
- ΠΠΎΡΠ±ΡΠ½ΠΎΠ²Π° Π.Π. ΠΠ½Π°ΡΡΡΠΎΠ·ΠΎΠ» ΠΊΠ°ΠΊ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π° Π°Π΄ΡΡΠ²Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π² ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅ // Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ, — 2002, — β Π‘.35−37.
- ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅Ρ Π‘Π‘Π‘Π . XI-Π΅ ΠΈΠ·Π΄. — ΠΡΠΏ. 1,2. -Π.-.ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1987.
- ΠΠ°ΡΠΊΠΎΠ²ΡΠΊΠΈΠΉ Π. Π. Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΠΠ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ' Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²//Π€Π°ΡΠΌΠ°ΡΠ΅ΠΊΠ°.— 1998.— № 3.— Π‘. 3−7.
- ΠΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΠΠΠΈΠ‘Π Π Π€ «ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²». Π., 2004.
- Π‘ΡΡΡΠΊΠΈΠ½ Π.Π., ΠΡΠΈΠΊΡΠΎΠ½ Π. Π., ΠΡΠ°ΡΠ΄Π΅ Π. Π. ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π²ΡΡΠΎΠΊΠΎΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠ½Π°Ρ Ρ ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΡ. Π.:Π₯ΠΈΠΌΠΈΡ, 1986. -312Ρ.
- ARIMIDEX (Anastrozole). In Physicians' Desk Reference (PDR) 2004, (pp.653−658), 58lh Edition 2004 by Medical Economics Company.
- Arimidex (Anastrozole), Product Monograph 2003 (pp. 1−32), AstraZeneca. Internet www.astrazeneca.ca (Access on 12 March 2007).
- Arora A., Potter J.F. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer // J. Am.
- Geriatr. Soc.- 2004, — N 4.- P.611 -616.
- Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 2001- 76(1−5): 199−202.
- British Pharmacopeia, 2005.
- Brodie A, Jelovac D, Long Π J. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clinical Cancer Research 2003- 9(1 Pt 2): 455S-9S.
- Brodie A, Lu Q, Long B. Aromatase and its inhibitors.
- Journal of Steroid Biochemistry and Molecular Biology 1999- 69: 205 210.
- Bressole F., Bromet-Petit M., Audran M. Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics // J. Chromatogr. B. 1996. V. 686. № 1. P. 3−10.
- Bulun S. E., Simpson E. R. Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat., 30: 19−29, 1994.
- Buzdar AU. Pharmacology and Pharmacokinetics of the Newer Generation Aromatase Inhibitors. Clinical Cancer Research 2003- 9:468 472.
- Buzdar AU, Robertson JF, Eiermarm W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generationaromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002- 95(9): 2006−16.
- Clinical pharmacology, preclinical pharmacology and toxicology.
- Arimidex (anastrozole). Advanced breast cancer, Monograph 2002, AstraZeneca, International Edition, pp.51−58. Internet www.arimidex.net (Access on 12 March 2007).
- Detre S., Salter J., Barnes D. M., Riddler S., Hills M. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int. J. Cancer, 81: 309−313, 1999.
- Dowsett M, Lonning PE. Anastrozole-a new generation in aromatase inhibition: clinical pharmacology. Oncology 1997- 54(Suppl 2): 11−4.
- Dowsett M., Jones A., Johnston S. R. D. In vivo measurement of aromatase inhibition by letrozole (CGS 20 267) in postmenopausal patients with breast cancer. Clin. Cancer Res., 1: 1511−1515, 1995.
- Dukes M. The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology 1997- 54 (Suppl 2): 6−10.
- Dukes M, Edwards PN, Large M, Smith IK, Boyle T. The preclinical pharmacology of «Arimidex» (anastrozole- ZD1033)-a potent, selective aromatase inhibitor. Journal of Steroid Biochemistry and Molecular Biology 1996- 58(4): 439−45.
- Edery M., Goussard J., Dehennin L., Scholler R., Reiffsteck J.,
- Drosdowsky M. A. Endogenous oestradiol-17-Π concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. Eur. J. Cancer, 17: 115−120, 1980.
- Ellis P. A., Sacconi-Jotti G., Clarke R., Johnston S. R. D., Anderson E., Howell A. Induction of apoptosis by tamoxifen and ICI 182 780 in primary breast cancer. Int. J. Cancer, 72: 608−613, 1997.
- Ellis P. A., Smith I. E., Detre S., Burton S. A. Reduced apoptosis and proliferation and increased bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat., 48: 107−116, 1998.
- Geisler J., Bemtsen H., Lenning P. E. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol, and estrone sulphate levels in breast cancer tissue. J. Steroid Biochem. Mol. Biol., 72: 259 264, 2000.
- Geisler J, Lonning PE. Aromatase Inhibition: Translation into a Successful Therapeutic Approach. Clinical Cancer Research 2005- 11(8):2809−2821.
- Gibaldi M, Perrier D. Noncompartmental Analysis Based on Statistical Moment Theory. In: Dekker M, Inc. Pharmacokinetics, 2nd ed. New York and Basel, 1982: 409−417.
- Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metabolism and Disposition 1997- 25(5): 598−602.
- Hauschke D, Stcinijans VW, Dilctti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992−30 Suppl 1: S37−43.
- Hauschke D, Sieinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm 1992−20(5):557−56I.
- Hayward J. L., Rubens R. D., Carbone P. P., Heuson J-C., Kumaoka S., Segaloff A. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer, 35: 292−298, 1977.
- Horwitz Π. Π., McGuire W. L., Pearson Π. H., Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (Wash. DC)., 189: 726−727, 1975.
- Hozumi Y. Hakamata Y.Sasanuma H. Ogura S, Nagai H. Effects of anastrozole on lipid metabolism compared with tamoxifen in rats. Breast Cancer Research and Treatment 2002- 76(2): 131−6.
- Karifes H. T, Shiu G, Shah V.P. Validation of bioanalytical methods // Pharmaceutical Research. 1991. V. 8. № 4. P. 421−425.
- Landeghem A. A. J. v, Poortman J, Nabuurs M, Thijssen J. H. H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res, 45: 2900−2906, 1985.
- Lenning P. E, Bakke P, Thorsen T, Olsen B, Gulsvik A. Plasma levels of estradiol, estrone, estrone sulfate, and sex hormone binding globulin in patients receiving rifampicin. J. Steroid Biochem, 33: 631−635, 1989.
- Lennmg P. E, Elcse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J. Steroid Biochem. Mol. Biol, 55: 409−412, 1995.
- Lonning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment 1998- 49 Suppl 1: S53−57.
- Lonning P, Pfister Ch, Martoni A, Zamagni Π‘ Pharmacokinetics of Third-Generation Aromatase Inhibitors. Seminars in Oncology 2003 -4 (suppl 14): 23−32.
- Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A.
- The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer
- Research and Treatment 1999- 57(2): 183−92.
- Lu Q, Yue W, Wang J. Liu Y.Long B. Brodie A. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Research and Treatment 1998- 50(1): 63−71
- Masiekowski P., Breathnach R., Bloch J., Gannon K., Krust A., Chambon P. Cloning of cDNA sequences of hormone-regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res., 10: 7895−7903, 1982.
- Maynard P. V., Brownsey B. G., Griffith K. Oestradiol levels in fractions of human breast tumours. J. Endocrinol., 77: P62-P63, 1978.
- Miller W. R. Importance of intratumour aromatase and its susceptibility to inhibitors Dowsett M. eds.. Aromatase Inhibition—Then, Now, and Tomorrow: Parthenon Publishing Group London 1994.
- Millington D. S. Determination of hormonal steroid concentrations in biological extracts by high resolution mass fragmentography. J. Steroid Biochem., 6: 239−245, 1975.
- Newby J. C., Johnston S. R. D., Smith I. E., Dowsett M. Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res., 3: 1643−1651, 1997.
- Odum J, Ashby J. Detection of aromatase inhibitors in vitro using rat ovary microsomes. Toxicology Letters 2002- 129(1−2): 119−22.
- O’Neil MJ, Smith A, Heckelman PE. Anastrozole. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. (p.633), thirteenth ed. 2001 by Merck&Co, INC., Whitehouse Station, NJ, USA.
- Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster A. Arimidex: A new Oral. Once A Day Aromatase Inhibitor. J Steroid Biochemistry and Molecular Biology 1995- 53: 175−179.
- Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Research and Treatment 1994- 30(1): 103−11.
- Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., Secreto G. Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues. J. Steroid Biochem. Mol. Biol., 52: 541−546, 1995.
- Reed M. J., Aheme G. W., Ghilchik M. W., Patel S., Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int. J. Cancer, 49: 562−565, 1991.
- Reed M. J., Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr. Rev., 18: 701−715, 1997.
- Reed M. J., Topping L., Coldham N. G., Purohit A., Ghilchik M. W., James V. H. T. Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. J. Steroid Biochem. Mol. Biol., 44: 589−596, 1993.
- Santner S. J., Feil P. D., Santen R. J/In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab., 59: 29−33, 1984.
- Santner S. J., Leszcynski D., Wright C., Manni A., Feil P. D., Santen R. J. Estrone sulfate: a potential source of estradiol in human breast cancer tissue. Breast Cancer Res. Treat., 7: 35−44, 1986.
- Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987−15:657−80.
- The United States Pharmacopeia XXVIII.
- Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Research 2003- 63(22): 8037−50.
- Thorsen Π’., Tangen M., St0a K. F. Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol. Eur. J. Cancer Clin. Oncol., 18: 333−337, 1982.
- Turner KJ, Morley M. Atanassova N, Swanston ID, Sharpe RM. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. Joumal-of-endocrinology 2000- 164(2): 225−38.
- Valient K., Mistry P., Griffith K., Maynard P. W. Endogenous Π‘19-steroids and oesti-adiol levels in human primary breast tumour tissues and their correlation 'with androgen and oestrogen receptors. J. Steroid Biochem., 24: 1117−1125, 1986.
- Wagner J. G., Fundamentals of clinical pharma-cokinetics, Hamilton, 1975.
- Wellington K, Faulds DM. Anastrozole in early Breast cancer. Drugs 2002- 62:2483−2490.
- Wiesemann LR, Adkins JC. Anastrozoie. A Review of its Use in the Management of Postmenopausal Women with Advanced Breast Cancer. Drugs&Aging 1998- 13 (4): 321−332.
- Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. British Journal of Cancer 1996- 73(4): 543−8.
- Yuan J, Wang PQ, Ge SR, An FR, Shi AG, Chen J, Liang JY. Pharmacokinetics of anastrozole in Chinese male volunteers. Acta Pharmacol Sin. 2001 Jun-22(6):573−6.